EMCURE
Ahead of Market: 10 things that will decide stock market action on Monday
Sensex and Nifty ended lower during Muhurat Trading on November 8, snapping a six-session winning streak. Nifty slipped below 25,000 as investors booked profits. However, broader market sentiment remained positive, with 2,716 NSE stocks advancing against 736 declines.
PSBs, pharma and defence: HDFC Securities CEO names Samvat 2083’s dark horses
HDFC Securities MD and CEO Dhiraj Relli identifies public sector banks, pharmaceuticals and defence as potential outperformers in Samvat 2083. He favours largecaps for valuation comfort, highlights selective stock opportunities and urges investors to prioritise earnings visibility and disciplined asset allocation.
Ahead of Market: 10 things that will decide stock market action on Friday
Indian markets staged a powerful rally, with Sensex jumping 2,009 points and Nifty gaining 576 points. Improved global sentiment, easing crude prices, US midterm election results, foreign investor buying and strong Q2 earnings lifted market capitalisation above Rs 500 lakh crore.
Ahead of Market: 10 things that will decide stock market action on Thursday
Indian markets extended their rally, with Sensex gaining 384 points to 77,301 and Nifty rising 150 points to 23,961, marking two-month highs. Positive sentiment, strong earnings, festive demand and buying across mid- and small-caps supported gains.
Emcure Pharma shares hit 10% upper circuit after FY27 guidance hike; Jefferies raises target price by 8%
Emcure Pharma shares hit a 10% upper circuit after strong Q2 FY27 results prompted the company to raise its full-year growth guidance. Brokerages turned more positive, citing robust international business, improving domestic growth and a strong product pipeline.
Emcure Pharma Q2 Results: Profit jumps 29% to Rs 325 crore
Emcure Pharmaceuticals Ltd has posted a remarkable consolidated net profit of Rs 325.06 crore for the September quarter, reflecting substantial growth. Revenue surged from Rs 2,269.82 crore to Rs 2,820.47 crore during this period, with international operations increasing by 34 per cent. Additionally, domestic revenue witnessed an 11.1 per cent rise, as company leaders expressed confidence in sustaining this positive trend through the latter half of FY27.
Emcure Pharma shares jump 7% after Q2 profit rises 29% YoY to Rs 325 crore
Emcure Pharmaceuticals shares rose up to 7.3% after the company reported a 29.3% year-on-year increase in Q2 FY27 profit to Rs 325.1 crore. Revenue grew 24.3%, while EBITDA rose 30.9%, supported by strong international business growth.
Stocks in news: ITC, Marico, SBI, Yatra Online, NSE, Container Corp and Sun Pharma
Indian equity benchmarks experienced gains, with Nifty nearing the 23,500 resistance level and strong corporate earnings reported. ITC faced a decline in consolidated net profit, impacted by the cigarette business, despite revenue growth. Marico saw a significant rise in net profit and expanding EBITDA margins during the quarter. Container Corporation of India reported a subdued performance with a slight decline in net profit compared to last year.
D-Street in gloomy mood, but Kotak sees 3 triggers for rebounds and adds 5 midcap stocks to portfolio
Dalal Street faces significant market challenges, leading Kotak Institutional Equities to spotlight selective stock value. With large-cap stocks in view, the impact of geopolitical strife and fluctuating crude oil prices weighs heavily on investor sentiment. The brokerage sees potential recovery catalysts in peace talks regarding the Iran-US situation and favorable Q2 earnings.
AMFI reshuffle: NSE may get largecap status, SBI Fund Management may become midcap in H1 CY27
Nuvama expects NSE to enter the largecap category and SBI Funds Management to become a midcap in AMFI’s H1 CY27 reshuffle. Bosch, Siemens Energy India and others may be upgraded, while several largecaps could move down. The revised classification will take effect from February 1, 2027, after H2 CY26 market-cap rankings.
Ahead of Market: 10 things that will decide stock market action on Monday
Indian equities extended their recovery, with Nifty gaining 0.33% as moderation in crude and global yields supported sentiment. Sensex slipped 0.03%, while broader markets outperformed. Here are 10 key factors that could influence Friday’s market action.
F&O Talk: Nifty has slipped below its crucial support, says Sudeep Shah; picks 5 stocks for next week
After a turbulent trading day, Indian stock indices bounced back significantly as oil prices and bond yields eased. The Sensex and Nifty ended with modest declines, having experienced deeper dips earlier. Previous climbs in crude oil prices and geopolitical issues had weighed down on investor confidence. Analysts suggest maintaining caution and closely watching Nifty’s support and resistance levels, highlighting particular metal stocks and equities to watch for the week ahead.
DRL, Emcure get approval to make breakthrough HIV drug
India's drug regulator has cleared the path for local lenacapavir manufacturing. Two Indian pharmaceutical companies received waivers for local clinical trials. This move will improve access to the HIV prevention injection. Lenacapavir is a breakthrough twice-yearly injection for HIV prevention. Patient groups had urged the regulator to expedite this process.
Emcure Pharma net profit up 36% at Rs 292 crore
Emcure Pharmaceuticals reported a 23% revenue increase in the first quarter. Ebitda grew 25.8% with improved margins, reflecting productivity gains. Net profit saw a significant 36.2% rise during the period. The company began its five-year plan on a strong footing for FY27. Emcure also completed the acquisition of a minority stake in Gennova Biopharmaceuticals.
Emcure Pharma Q1 profit jumps 36%, revenue rises 23%; appoints Samit Mehta as COO
"We have begun FY27, the second year of our five-year plan—on a strong footing. FY26 was about putting the building blocks in place across teams, portfolio, integration and operating discipline. FY27 is about delivery, and Q1 is an encouraging early signal,” said Satish Mehta, Managing Director and CEO Emcure Pharmaceuticals.
Emcure buys remaining 12.05% in Gennova to take full control
Emcure Pharma is acquiring the remaining stake in Gennova Biopharmaceuticals. This move simplifies ownership and sharpens strategic focus for the subsidiary. Gennova will now be led by Samit Mehta for its next growth phase. The company will continue leveraging its biomanufacturing platforms for new products. Gennova's former CEO Sanjay Singh has divested its mRNA business.
Emcure, Sanofi sign distribution pact for oral anti-diabetic products in India
Emcure Pharmaceuticals and Sanofi India have announced a distribution agreement. Emcure will promote Sanofi India's oral anti-diabetic products like Amaryl and Cetapin. Sanofi India will continue to manufacture these brands. This collaboration aims to make these medicines more accessible across India. The partnership will benefit patients and healthcare professionals. There will be no staff transition from Sanofi India to Emcure.
Emcure Pharmaceuticals IPO: 10 things to know before subscribing to the issue
Emcure Pharmaceuticals IPO is scheduled to open for subscription on July 3 and will close on July 5. The company aims to raise approximately Rs 1,952 crore through the public offer. Market analysts indicate that the current GMP of the pharma company stands at Rs 260 in the unlisted market.
Emcure and its subsidiary Gennova settle legal dispute with HDT Bio over mRNA technology
Emcure Pharmaceuticals and its subsidiary Gennova have resolved all legal disputes with US-based HDT Bio Corp. The parties have entered into a long-term agreement to develop mRNA vaccines against various infectious diseases in India and other countries. As part of their agreement, HDT has granted a license to Gennova to use HDT's patented mRNA vaccine technology in multiple fields
Load More
